Why Pressure BioSciences’ (PBIO) Addition to the Richmond Club Index Matters

Most investors are familiar with Warren Buffett’s Berkshire Hathaway or George Soros’ Quantum Fund, which have returned 20% and 30% on an annualized basis over the course of several decades. Over the past 17 years, the Richmond Club has helped its membership base consisting of investment advisors, fund managers, accredited investors, analysts, and media members generate an annualized return of about 17% on its indexed companies.

The Richmond Club carefully screens thousands of publicly-traded companies, chooses a handful of them to interview, and then selects the best company among the finalists. In general, the stocks chosen for the Index have high growth potential and are undervalued by the market due to a lack of investment exposure. Inclusion in the Index provides the necessary exposure to close the valuation gap and generate above-market returns for members.

Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the development and sale of broadly enabling pressure cycling technology (PCT)-based sample preparation solutions to the life sciences industry, was recently selected for inclusion in the Richmond Club Index. On April 13th, the company gave a presentation to the Richmond Club near the Toronto Stock Exchange and a video of the presentation will be made available to online viewers shortly afterwards.

“We are very pleased that Pressure BioSciences has been selected for addition into the Richmond Club Index,” said Pressure BioSciences President and CEO Mr. Richard T. Schumacher. “We are particularly delighted by the exposure that PBI will be getting to the Richmond Club’s 500+ members, comprised of an assortment of investors and investing professionals, many of whom will be hearing the PBI story for the first time.”

The company has made tremendous strides over the past few quarters in growing its underlying business and reaching a wider investment audience, which means that investors may want to take a closer look at the stock.

SCIEX’s Platform for Distribution

Pressure BioSciences announced an exclusive co-marketing agreement earlier this year with SCIEX, a subsidiary of Danaher Corporation (NYSE: DHR) and a global leader in life sciences analytical technologies. The two companies will jointly promote PBI’s PCT-based sample preparation systems and SCIEX’s mass spectrometry equipment, which combine to generate superior insights for the life sciences industry, particularly in the field of proteomics (proteins).

Many prominent scientists are already starting to see the potential for the PCT-SWATH combination. Professor Ruedi Aebersold, a world renowned expert in the proteomics field who heads up the Institute of Molecular Systems Biology at ETH in Zurich, Switzerland, said that PCT-SWATH “should increase the chance for biomarker discovery, potentially leading to significant improvements in healthcare, including personalized medicine.”

In essence, PBI’s PCT technology maximizes the proteome coverage in samples, particularly when dealing with small tissue biopsies associated with clinical tumor samples. These small sizes limited the use of mass spectrometry equipment – including the SWATH technologies – in the past when it came to crucial proteomics analysis for clinical research. However, the combination of PCT and SWATH enables researchers to use these small tissue biopsy samples and generate accurate results in just hours.  How interesting would this be for Pressure BioSciences if this method became an approved method for analyzing cancer biopsy tissues in hospitals and clinics worldwide?

The increased attention could lead to similar agreements with other industry leaders like Thermo Fischer Scientific Inc. (NYSE: TMO) or Waters Corporation (NYSE: WAT). With its modest market cap of about $10 million, the company could also become an acquisition target for one of these companies looking to gain a competitive edge in an increasingly commoditized market.

Richmond Club Index Enhances Awareness

Pressure BioSciences’ stock has risen more than 30% since the beginning of the year, thanks in part to its SCIEX agreement, and to its success in closing an oversubscribed $5 million PIPE financing. Management plans to pursue an up-listing to a national exchange like the NASDAQ later this year, which could further increase its visibility within the investment community by opening the door to institutional investors that are forbidden from buying over-the-counter stocks.

The Richmond Club could provide much-needed investor awareness. In other words, the group could provide a key distribution channel for its stock in much the same way that SCIEX has become a vital distribution channel for its products. The group’s wide following in the investment community could open the door to both near-term and long-term investment, particularly when it up-lists to a national stock exchange.

Investors in early stage biotechnology companies, like NanoString Technologies Inc. (NSTG), NeoGenomics Inc. (NASDAQ: NEO), or Protea Biosciences Group (OTC: PRGB) may want take a closer look at the company before the company is widely discovered by the rest of the market.

Looking Ahead

Pressure BioSciences may be significantly undervalued with its $10 million market capitalization in light of numerous upcoming catalysts. In terms of its business, the company’s agreement with SCIEX provides vital distribution for its products that should be reflected in future earnings. The Richmond Club’s decision to include the company in its Index could open the door to a wider investment base and ultimately unlock value in the stock.

For more information, visit the company’s website at www.pressurebiosciences.com.